NLRP3 and Hepatic fibrosis: Previous studies have demonstrated that NLRP3 activation contributes to renal fibrosis (You et al., 2022), hepatic fibrosis (Niu et al., 2022; Yuan et al., 2022), and pulmonary fibrosis (Joshi et al., 2022), and inhibition of NLRP3 activation reduces the degree of fibrosis.